AR055052A1 - Metodos para tratamiento de trastornos inmunes asociados con transplante de injerto con moleculas mutantes del antigeno 4 del linfocito t citotoxico (ctla4) solubles - Google Patents

Metodos para tratamiento de trastornos inmunes asociados con transplante de injerto con moleculas mutantes del antigeno 4 del linfocito t citotoxico (ctla4) solubles

Info

Publication number
AR055052A1
AR055052A1 ARP060101377A ARP060101377A AR055052A1 AR 055052 A1 AR055052 A1 AR 055052A1 AR P060101377 A ARP060101377 A AR P060101377A AR P060101377 A ARP060101377 A AR P060101377A AR 055052 A1 AR055052 A1 AR 055052A1
Authority
AR
Argentina
Prior art keywords
antigen
ctla4
treatment
disorders associated
graft
Prior art date
Application number
ARP060101377A
Other languages
English (en)
Spanish (es)
Inventor
David Hagerty
James Rusnak
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR055052A1 publication Critical patent/AR055052A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Medical Informatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ARP060101377A 2005-04-06 2006-04-06 Metodos para tratamiento de trastornos inmunes asociados con transplante de injerto con moleculas mutantes del antigeno 4 del linfocito t citotoxico (ctla4) solubles AR055052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66877405P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
AR055052A1 true AR055052A1 (es) 2007-08-01

Family

ID=36694299

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101377A AR055052A1 (es) 2005-04-06 2006-04-06 Metodos para tratamiento de trastornos inmunes asociados con transplante de injerto con moleculas mutantes del antigeno 4 del linfocito t citotoxico (ctla4) solubles

Country Status (25)

Country Link
US (2) US7482327B2 (enExample)
EP (1) EP1868635B1 (enExample)
JP (1) JP2008535841A (enExample)
KR (1) KR101235484B1 (enExample)
CN (1) CN101198347A (enExample)
AR (1) AR055052A1 (enExample)
AU (1) AU2006231622B2 (enExample)
BR (1) BRPI0608144A2 (enExample)
CA (1) CA2603970A1 (enExample)
CY (1) CY1119145T1 (enExample)
DK (1) DK1868635T3 (enExample)
EA (1) EA013122B1 (enExample)
ES (1) ES2634260T3 (enExample)
HR (1) HRP20171121T8 (enExample)
IL (1) IL186189A (enExample)
LT (1) LT1868635T (enExample)
ME (1) ME02930B (enExample)
MX (1) MX2007012222A (enExample)
NO (1) NO342966B1 (enExample)
NZ (2) NZ561655A (enExample)
PL (1) PL1868635T3 (enExample)
PT (1) PT1868635T (enExample)
RS (1) RS56138B1 (enExample)
SI (1) SI1868635T1 (enExample)
WO (1) WO2006108035A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2006108035A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
EP2612867A1 (en) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
US20110159023A1 (en) * 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
EP2365823B1 (en) * 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US20100297123A1 (en) * 2009-05-15 2010-11-25 Garrison Fathman C Combination therapy to inhibit t cell effector function
US8329867B2 (en) * 2010-02-19 2012-12-11 Xencor, Inc. CTLA4-Ig immunoadhesins
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
SG188471A1 (en) 2010-09-08 2013-04-30 Yeda Res & Dev An immunosuppressive drug combination for a stable and long term engraftment
PT2613801T (pt) 2010-09-08 2016-09-12 Yeda Res & Dev Utilização de células t de memória central anti-terceiros no tratamento anti-leucemia/linfoma
RU2636503C2 (ru) 2011-09-08 2017-11-23 Иеда Рисеч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
WO2014160822A1 (en) * 2013-03-28 2014-10-02 Bristol-Myers Squibb Company Methods for identifying patients at risk for costimulation blockade resistant rejection
CN104673822A (zh) * 2013-11-27 2015-06-03 深圳先进技术研究院 一种重组载体及其制备方法和应用
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
CN106132429A (zh) 2014-03-19 2016-11-16 百时美施贵宝公司 使用针对cd40l的域抗体治疗移植物排斥的方法
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
CN108135938A (zh) 2015-07-16 2018-06-08 耶达研究及发展有限公司 基因修饰的抗第三方中央型记忆t细胞及其在免疫疗法中的用途
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
CN110392736A (zh) 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019246577A1 (en) 2018-06-22 2019-12-26 Mayo Foundation For Medical Education And Research Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality
WO2020010259A1 (en) * 2018-07-06 2020-01-09 Mayo Foundation For Medical Education And Research Methods and materials for improving transplant outcomes
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
CN115089718B (zh) * 2021-11-30 2024-05-28 杭州瑞普晨创科技有限公司 用于异种移植的免疫抑制剂组合和免疫抑制方法
KR20240122658A (ko) 2023-02-03 2024-08-13 이뮤노바이옴 주식회사 이식 거부 반응의 예방 또는 치료용 조성물
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
ATE390931T1 (de) * 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006108035A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules

Also Published As

Publication number Publication date
BRPI0608144A2 (pt) 2009-11-17
PT1868635T (pt) 2017-07-27
LT1868635T (lt) 2017-07-10
JP2008535841A (ja) 2008-09-04
AU2006231622A1 (en) 2006-10-12
AU2006231622B2 (en) 2012-07-05
HRP20171121T1 (hr) 2017-10-06
NO342966B1 (no) 2018-09-10
WO2006108035A1 (en) 2006-10-12
CN101198347A (zh) 2008-06-11
HRP20171121T8 (hr) 2017-11-03
EP1868635B1 (en) 2017-05-17
PL1868635T3 (pl) 2017-10-31
SI1868635T1 (sl) 2017-07-31
NZ561655A (en) 2010-01-29
US20100041602A1 (en) 2010-02-18
KR20070119728A (ko) 2007-12-20
NZ576434A (en) 2010-06-25
CY1119145T1 (el) 2018-02-14
IL186189A0 (en) 2008-01-20
NO20075078L (no) 2008-01-04
US20070009511A1 (en) 2007-01-11
EA013122B1 (ru) 2010-02-26
CA2603970A1 (en) 2006-10-12
RS56138B1 (sr) 2017-10-31
US7482327B2 (en) 2009-01-27
ES2634260T3 (es) 2017-09-27
KR101235484B1 (ko) 2013-02-22
MX2007012222A (es) 2007-12-06
DK1868635T3 (en) 2017-09-11
EP1868635A1 (en) 2007-12-26
ME02930B (me) 2018-04-20
EA200702180A1 (ru) 2008-10-30
IL186189A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
AR055052A1 (es) Metodos para tratamiento de trastornos inmunes asociados con transplante de injerto con moleculas mutantes del antigeno 4 del linfocito t citotoxico (ctla4) solubles
GEP20053658B (en) Soluble CTLA4 Mutant Molecules and Uses Thereof
SA520420301B1 (ar) مستقبلات خيمرية لشبيه الدلتا 3 وطرق استخدامها
PH12020551261A1 (en) Il-15 conjugates and uses thereof
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
MX2021002764A (es) Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
IS6667A (is) Aðferðir til að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4 sameind
GEAP202415222A (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
AR059605A1 (es) Metodos para el uso de anticuerpos contra il-22 humana
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
IL214325A (en) Antibody against cmet, a drug that includes and uses it
MX2009010444A (es) Anticuerpo anti-epcam y usos del mismo.
EP4538295A3 (en) Antigen binding molecules and methods of use thereof
SG163615A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MX2022012991A (es) Anticuerpos anti-vista humanos y uso de estos.
DE602005021694D1 (de) Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
SA521421049B1 (ar) مستقبلات خيمرية لمستضدات بشروية ستة عبر الغشاء للبروستاتة 1 وطرق استخدامها
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
AR066649A1 (es) Reovirus mutantes y metodos de elaboracion y uso de los mismos
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy

Legal Events

Date Code Title Description
FB Suspension of granting procedure